Log in

NYSE:HAE - Haemonetics Stock Price, Forecast & News

$100.95
-3.89 (-3.71 %)
(As of 03/29/2020 04:00 PM ET)
Today's Range
$98.25
Now: $100.95
$103.82
50-Day Range
$74.34
MA: $106.14
$120.82
52-Week Range
$63.41
Now: $100.95
$140.36
Volume387,710 shs
Average Volume721,727 shs
Market Capitalization$5.08 billion
P/E Ratio65.98
Dividend YieldN/A
Beta0.67
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. The company also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, it offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, a surgical blood salvage system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; OrthoPAT, a perioperative autotranfusion system for orthopedic procedures; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.
Read More
Haemonetics logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
CUSIP40502410
Phone781-848-7100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$967.58 million
Cash Flow$4.46 per share
Book Value$13.09 per share

Profitability

Net Income$55.02 million

Miscellaneous

Employees3,216
Market Cap$5.08 billion
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive HAE News and Ratings via Email

Sign-up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter.


Haemonetics (NYSE:HAE) Frequently Asked Questions

How has Haemonetics' stock been impacted by COVID-19 (Coronavirus)?

Haemonetics' stock was trading at $103.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, HAE shares have decreased by 2.7% and is now trading at $100.95. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Haemonetics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Haemonetics.

When is Haemonetics' next earnings date?

Haemonetics is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Haemonetics.

How were Haemonetics' earnings last quarter?

Haemonetics Co. (NYSE:HAE) issued its quarterly earnings data on Tuesday, February, 4th. The medical instruments supplier reported $0.94 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.76 by $0.18. The medical instruments supplier earned $259 million during the quarter, compared to analysts' expectations of $255.40 million. Haemonetics had a net margin of 7.98% and a return on equity of 27.78%. The company's revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.63 earnings per share. View Haemonetics' earnings history.

What guidance has Haemonetics issued on next quarter's earnings?

Haemonetics updated its FY 2020 Pre-Market earnings guidance on Tuesday, February, 4th. The company provided earnings per share guidance of 3.30-3.40 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.18. The company issued revenue guidance of $996.606M - 1.016 billion, compared to the consensus revenue estimate of $1 billion.

What price target have analysts set for HAE?

6 brokerages have issued 12 month price targets for Haemonetics' shares. Their forecasts range from $138.00 to $150.00. On average, they anticipate Haemonetics' share price to reach $142.67 in the next year. This suggests a possible upside of 41.3% from the stock's current price. View analysts' price targets for Haemonetics.

Has Haemonetics been receiving favorable news coverage?

Media stories about HAE stock have been trending somewhat positive on Sunday, InfoTrie reports. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Haemonetics earned a daily sentiment score of 1.9 on InfoTrie's scale. They also assigned media stories about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutHaemonetics.

Are investors shorting Haemonetics?

Haemonetics saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 1,760,900 shares, an increase of 96.7% from the February 27th total of 895,400 shares. Based on an average daily volume of 472,000 shares, the days-to-cover ratio is currently 3.7 days. Currently, 3.5% of the shares of the company are sold short. View Haemonetics' Current Options Chain.

Who are some of Haemonetics' key competitors?

What other stocks do shareholders of Haemonetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include Endologix (ELGX), Align Technology (ALGN), Chipotle Mexican Grill (CMG), Zoetis (ZTS), Apache (APA), NVIDIA (NVDA), Micron Technology (MU), Nexstar Media Group (NXST), Insperity (NSP) and Pfizer (PFE).

Who are Haemonetics' key executives?

Haemonetics' management team includes the following people:
  • Mr. Christopher Simon, CEO, Pres & Director (Age 55)
  • Mr. William P. Burke, CFO & Exec. VP
  • Ms. Michelle L. Basil, Exec. VP, Gen. Counsel & Sec.
  • Ms. Jacqueline D. Scanlan, Sr. VP of Global HR
  • Mr. Dan Goldstein, Principal Accounting Officer, VP & Corp. Controller (Age 42)

What is Haemonetics' stock symbol?

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

Who are Haemonetics' major shareholders?

Haemonetics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (5.36%), Renaissance Technologies LLC (4.85%), FMR LLC (4.22%), Jackson Square Partners LLC (3.54%), State Street Corp (3.26%) and Franklin Resources Inc. (2.03%). Company insiders that own Haemonetics stock include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Michelle L Basil, Neil Mr Ryding, Pedro P Granadillo, Richard J Meelia, Ronald G Gelbman, Said Bolorforosh and William P Mr Burke. View institutional ownership trends for Haemonetics.

Which institutional investors are selling Haemonetics stock?

HAE stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, AQR Capital Management LLC, Man Group plc, Eagle Asset Management Inc., PNC Financial Services Group Inc., Nuveen Asset Management LLC, Russell Investments Group Ltd., and Castleark Management LLC. Company insiders that have sold Haemonetics company stock in the last year include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Michelle L Basil, Ronald G Gelbman, Said Bolorforosh, and William P Mr Burke. View insider buying and selling activity for Haemonetics.

Which institutional investors are buying Haemonetics stock?

HAE stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, FMR LLC, Capital Research Global Investors, Westfield Capital Management Co. LP, Credit Suisse AG, MERIAN GLOBAL INVESTORS UK Ltd, MERIAN GLOBAL INVESTORS UK Ltd, and Jackson Square Partners LLC. View insider buying and selling activity for Haemonetics.

How do I buy shares of Haemonetics?

Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Haemonetics' stock price today?

One share of HAE stock can currently be purchased for approximately $100.95.

How big of a company is Haemonetics?

Haemonetics has a market capitalization of $5.08 billion and generates $967.58 million in revenue each year. The medical instruments supplier earns $55.02 million in net income (profit) each year or $2.39 on an earnings per share basis. Haemonetics employs 3,216 workers across the globe. View additional information about Haemonetics.

What is Haemonetics' official website?

The official website for Haemonetics is http://www.haemonetics.com/.

How can I contact Haemonetics?

Haemonetics' mailing address is 125 Summer Street, Boston MA, 02110. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]


MarketBeat Community Rating for Haemonetics (NYSE HAE)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  307 (Thanks for Voting!)
Underperform Votes:  410 (Thanks for Voting!)
Total Votes:  717
MarketBeat's community ratings are surveys of what our community members think about Haemonetics and other stocks. Vote "Outperform" if you believe HAE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HAE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Featured Article: What is Liquidity?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel